Strontium kinetics in metastasized prostatic carcinoma: a comparison with the predictions of impulse response function analysis.
Amongst patients referred for 89Sr palliation of disseminated prostatic carcinoma, we have found wide variations in extent of skeletal metastatic disease and in strontium renal plasma clearance. A numerical technique using impulse response function analysis is reviewed which enables the effect of such variations on the total body, plasma and metastatic strontium retention functions to be calculated. The prediction of the model are compared with kinetic data from patients presenting for radiostrontium therapy, and correlations that have important implications for 89Sr dosimetric studies are confirmed. The simplest kinetic data required to allow for these effects in studies of dose-response and haematological toxicity following radio-strontium treatment are discussed and attention is drawn to a small group of patients who may form a significant exception to the general model.
Wessex Regional Department of Nuclear Medicine, Southampton General Hospital, UK.
G M
GM
Blake
M A
MA
Zivanovic
J M
JM
Gray
D001859:Bone Neoplasms / Q000378:metabolism / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D008159:Lumbar Vertebrae; D008297:Male; D008657:Metabolic Clearance Rate; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D011829:Radiation Dosage; D013125:Spinal Neoplasms / Q000378:metabolism / Q000532:radiotherapy / Q000556:secondary; D013326:Strontium Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use
D013326:Strontium Radioisotopes